Drug survival of secukinumab in real‐world plaque psoriasis patients: A 52‐week, multicenter, retrospective study
暂无分享，去创建一个
[1] S. Hsu,et al. Loss of efficacy of secukinumab for psoriasis at 24 to 32 weeks: Update and commentary. , 2017, Journal of the American Academy of Dermatology.
[2] S. Hsu,et al. Loss of efficacy of secukinumab for psoriasis at 24 to 32 weeks. , 2016, Journal of the American Academy of Dermatology.
[3] A. Menter,et al. Drug survival of biologic therapy in a large, disease‐based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR) , 2016, Journal of the European Academy of Dermatology and Venereology : JEADV.
[4] G. Girolomoni,et al. Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: A randomized, double-blind, noninferiority trial (SCULPTURE). , 2015, Journal of the American Academy of Dermatology.
[5] L Puig,et al. Treatment goals for psoriasis: Should PASI 90 become the standard of care? , 2015, Actas dermo-sifiliograficas.
[6] B. Elewski,et al. Secukinumab in plaque psoriasis--results of two phase 3 trials. , 2014, The New England journal of medicine.
[7] E. G. Lantarel,et al. Treatment goals in psoriasis , 2022 .